Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 9.12
(-0.44%)
CNY 9.12
(-0.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 897.49 Million CNY | 104.11% |
| 2022 | 439.7 Million CNY | 262.39% |
| 2021 | -270.78 Million CNY | 76.31% |
| 2020 | -1.14 Billion CNY | -1196.77% |
| 2019 | -88.12 Million CNY | 15.35% |
| 2018 | -104.11 Million CNY | 42.15% |
| 2017 | -179.96 Million CNY | -44.37% |
| 2016 | -124.65 Million CNY | 5.26% |
| 2015 | -131.58 Million CNY | -235.77% |
| 2014 | 96.92 Million CNY | 44.32% |
| 2013 | 67.15 Million CNY | 71.52% |
| 2012 | 39.15 Million CNY | 39.29% |
| 2011 | 28.1 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 605.03 Million CNY | -36.38% |
| 2024 Q1 | 912.01 Million CNY | 1.62% |
| 2024 Q2 | 951.02 Million CNY | 4.28% |
| 2023 Q3 | 850.15 Million CNY | -4.89% |
| 2023 Q4 | 897.49 Million CNY | 5.57% |
| 2023 Q1 | 826.39 Million CNY | 87.94% |
| 2023 FY | 897.49 Million CNY | 104.11% |
| 2023 Q2 | 893.84 Million CNY | 8.16% |
| 2022 Q4 | 439.7 Million CNY | 66.63% |
| 2022 Q3 | 263.88 Million CNY | 161.57% |
| 2022 Q2 | 100.88 Million CNY | 34.34% |
| 2022 FY | 439.7 Million CNY | 262.39% |
| 2022 Q1 | 75.09 Million CNY | 127.73% |
| 2021 Q1 | -927.98 Million CNY | 18.8% |
| 2021 Q3 | -646.69 Million CNY | 28.69% |
| 2021 Q4 | -270.78 Million CNY | 58.13% |
| 2021 FY | -270.78 Million CNY | 76.31% |
| 2021 Q2 | -906.89 Million CNY | 2.27% |
| 2020 Q1 | -312.25 Million CNY | -254.32% |
| 2020 FY | -1.14 Billion CNY | -1196.77% |
| 2020 Q4 | -1.14 Billion CNY | -305.87% |
| 2020 Q3 | -281.57 Million CNY | 21.53% |
| 2020 Q2 | -358.81 Million CNY | -14.91% |
| 2019 Q2 | 93.13 Million CNY | 357.1% |
| 2019 Q1 | -36.22 Million CNY | 65.21% |
| 2019 FY | -88.12 Million CNY | 15.35% |
| 2019 Q4 | -88.12 Million CNY | -212.43% |
| 2019 Q3 | 78.38 Million CNY | -15.83% |
| 2018 Q3 | -30.76 Million CNY | 2.56% |
| 2018 Q2 | -31.57 Million CNY | -281.47% |
| 2018 Q1 | -8.27 Million CNY | 95.4% |
| 2018 FY | -104.11 Million CNY | 42.15% |
| 2018 Q4 | -104.11 Million CNY | -238.36% |
| 2017 Q3 | -110.57 Million CNY | 14.93% |
| 2017 Q4 | -179.96 Million CNY | -62.76% |
| 2017 Q2 | -129.97 Million CNY | -139.07% |
| 2017 Q1 | -54.36 Million CNY | 56.39% |
| 2017 FY | -179.96 Million CNY | -44.37% |
| 2016 Q2 | -122.4 Million CNY | -746.97% |
| 2016 Q4 | -124.65 Million CNY | 15.36% |
| 2016 Q3 | -147.28 Million CNY | -20.32% |
| 2016 Q1 | -14.45 Million CNY | 89.02% |
| 2016 FY | -124.65 Million CNY | 5.26% |
| 2015 Q3 | 122.5 Million CNY | 19.85% |
| 2015 FY | -131.58 Million CNY | -235.77% |
| 2015 Q4 | -131.58 Million CNY | -207.41% |
| 2015 Q1 | 111.52 Million CNY | 15.07% |
| 2015 Q2 | 102.21 Million CNY | -8.35% |
| 2014 Q4 | 96.92 Million CNY | 0.0% |
| 2014 Q1 | 64.94 Million CNY | 0.0% |
| 2014 FY | 96.92 Million CNY | 44.32% |
| 2013 FY | 67.15 Million CNY | 71.52% |
| 2012 FY | 39.15 Million CNY | 39.29% |
| 2011 FY | 28.1 Million CNY | 0.0% |